FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.644,03 +3.803,93 (+6,94%)
Immatics N.V. (IMTX)
Dopo ore:
| Chiusura precedente | 10,89 |
| Aperto | 11,08 |
| Denaro | 10,75 x 100 |
| Lettera | 10,81 x 500 |
| Min-Max giorno | 10,74 - 11,18 |
| Intervallo di 52 settimane | 7,15 - 13,16 |
| Volume | |
| Media Volume | 427.040 |
| Capitalizzazione | 1,123B |
| Beta (5 anni mensile) | 0,68 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,29 |
| Prossima data utili | 14 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 18,73 |
GlobeNewswireImmatics Announces Second Quarter 2023 Financial Results and Business Update
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023Bristol Myers Squibb exercised first opt-in into
- GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2 trial underwayThe trial will evaluate safety, tolerability, and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumorsFirst clinical data expected in 2024 Tuebingen, Germany and Houston, Texas, August 10, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the disc
- GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.461. Additionally, Bristol Myers Squ
